Dao Wen Wang
Dao Wen Wang received an M.D. degree from Hubei Medical University, Hubei, China, in 1982, and an M.S. degree and a Ph.D. degree from Tongji Medical University, Wuhan, China, in 1988 and 1992, respectively. He works as a Full Professor in medicine and Director of Gene Therapy Center and Institute of Hypertension as well as Chief of the Department of Internal Medicine and Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science &Technology, Wuhan, China. During the period from 1982 to 1985, he was a Resident in internal medicine at Teaching Hospital of Hubei Medical University, Hubei, China, and in 1988¬—1989 Chief Resident and Physician in Charge at Cardiology Division of Internal Medicine, Tongji Hospital, Tongji Medical University, Hubei, China. Funds running in Wang’s laboratory are rAAV-mediated gene therapy of hypertension with Kallikrein (from Scientific Committee, Wuhan, 1999–2001), roles of renal arachidonic acid hydroxygenase in hypertension and renal function (funded by National Natural Scientific Foundation Committee, 2000–2002), regulatory effects of endothelial derived hyperpolarizing factors on eNOS genes (funded by National Natural Scientific Foundation Committee, 1999–2001), and analysis of risk factors of strokes (molecular mechanisms analysis) complicated by essential hypertension of Chinese (funded by China Central Government). Wang is a Member of the Chinese Medical Society and the American Heart Association. He serves as an Editor of Journal of Internal Intensive Medicine and Associate Chief Editor of Chinese Molecular Cardiology.
Biography Updated on 2 January 2011